Resistant hypertension and left ventricular hypertrophy: an overview

Thurmer, 1994, Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study, J Hypertens, 12, 481 Viera, 2010, Levels of blood pressure above goal and clinical inertia in a Medicaid population, Am J Hypertens, 4, 244, 10.1016/j.jash.2010.07.003 2007 Guidelines for the Management of Arterial Hypertension, 2007, The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens, 25, 1105, 10.1097/HJH.0b013e3281fc975a Volpe, 2007, Blood pressure control in Italy: results of recent surveys on hypertension, J Hypertens, 25, 1491, 10.1097/HJH.0b013e3280fa83a6 Hajjar, 2003, Trends in prevalence, awareness, treatment and control of blood pressure in the United States of America: 1988–2000, JAMA, 290, 199, 10.1001/jama.290.2.199 Llyod-Jones, 2000, Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community, Hypertension, 36, 594, 10.1161/01.HYP.36.4.594 Benetos, 2003, Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population, J Hypertens, 21, 1635, 10.1097/00004872-200309000-00011 Mancia, 2009, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document, J Hypertens, 27, 2121, 10.1097/HJH.0b013e328333146d Sehestedt, 2010, Subclinical organ damage and cardiovascular risk prediction, Blood Pressure, 19, 132, 10.3109/08037051.2010.483054 Devereux, 2004, Prognostic significance of left ventricular mass change during treatment of hypertension, JAMA, 292, 2350, 10.1001/jama.292.19.2350 Bombelli, 2009, Left ventricular hypertrophy increases cardiovascular risk independently of in- and out-of office blood pressure values, J Hypertens, 27, 2458, 10.1097/HJH.0b013e328330b845 Cuspidi, 2009, Cardio-renal organ damage and cardiovascular outcomes in hypertension, J Hypertens, 27, 702, 10.1097/HJH.0b013e3283295dbf De Ciuceis, 2007, Structural alterations of subcutaneous small arteries may predict major cardiovascular events in hypertensive patients, Am J Hypertens, 20, 846, 10.1016/j.amjhyper.2007.03.016 McAlister, 1996, Resistant hypertension: an overview, Can J Cardiol, 12, 822 Ram, 2003, Management of refractory hypertension, Am J Therapeut, 10, 122, 10.1097/00045391-200303000-00007 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Calhoun, 2008, AHA Scientific Statement. Resistant hypertension: diagnosis, evaluation, and treatment, Circulation, 117, e510, 10.1161/CIRCULATIONAHA.108.189141 Redon, 1998, Prognostic value of ambulatory blood pressure monitoring in refractory hypertension. A prospective study, Hypertension, 31, 712, 10.1161/01.HYP.31.2.712 Volpe, 2010, Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice, Expert Rev Cardiovasc Ther, 8, 811, 10.1586/erc.10.47 Goodfriend, 2004, Resistant hypertension, obesity, sleep apnea, and aldosterone theory and therapy, Hypertension, 40, 518, 10.1161/01.HYP.0000116223.97436.e5 Cuspidi, 1999, Blood pressure control in a hypertension hospital clinic, J Hypertens, 17, 835, 10.1097/00004872-199917060-00016 Veglio, 2001, Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension, Clin Exp Hypertens, 23, 203, 10.1081/CEH-100102660 Hansson, 1998, Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6 2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981 Pepine, 2003, A calcium antagonist vs a non calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study: a randomized controlled trial, JAMA, 290, 2805, 10.1001/jama.290.21.2805 Gorostidi, 2007, Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of 20,000 patient data base in Spain, J Hypertens, 25, 977, 10.1097/HJH.0b013e32809874a2 Hernandez-del Rey, 1998, Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect, Blood Press Monit, 3, 331 Cuspidi, 2001, High prevalence of cardiac and extracardiac target organ damage in refractory hypertension, J Hypertens, 19, 2063, 10.1097/00004872-200111000-00018 Salles, 2005, Combined QT interval and voltage criteria improve left ventricular hypertrophy detection in resistant hypertension, Hypertension, 46, 1207, 10.1161/01.HYP.0000185517.53179.43 Salles, 2006, Importance of the electrocardiographic strain pattern in patients with resistant hypertension, Hypertension, 48, 437, 10.1161/01.HYP.0000236550.90214.1c Castelpoggi, 2009, A blunted decrease in nocturnal blood pressure is independently associated with increased aortic stiffness in patients with resistant hypertension, Hypertens Res, 32, 591, 10.1038/hr.2009.71 Salles, 2009, Prognostic value of ventricular repolarization prolongation in resistant hypertension: a prospective cohort study, J Hypertens, 27, 1094, 10.1097/HJH.0b013e32832720b3 Salles, 2010, Prognostic significance of baseline and serial changes in electrocardiographic strain pattern in resistant hypertension, J Hypertens, 28, 1715, 10.1097/HJH.0b013e32833af39a Salles, 2010, Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension, Am Heart J, 159, 833, 10.1016/j.ahj.2010.02.012 Mathew, 2001, Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril, Circulation, 104, 1615, 10.1161/hc3901.096700 Ruilope, 2008, Left ventricular hypertrophy and clinical outcomes in hypertensive patients, Am J Hypertens, 21, 500, 10.1038/ajh.2008.16 Pierdomenico, 2010, Risk reduction after regression of echocardiographic left ventricular hypertrophy: a meta-analysis, Am J Hypertens, 23, 876, 10.1038/ajh.2010.80 Cuspidi, 2010, Lowering left ventricular mass in hypertension: a way to improve the prognosis?, Am J Hypertens, 23, 818, 10.1038/ajh.2010.95 de Faire, 1989, Regression of left ventricular hypertrophy on long-term treatment with captopril of severe hypertensives refractory to standard triple treatment, Eur J Clin Pharmacol, 37, 291, 10.1007/BF00679786 Julien, 1990, Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison, J Am Coll Cardiol, 16, 137, 10.1016/0735-1097(90)90470-A Gaddam, 2010, Rapid reversal of left ventricular hypertrophy and intracardiac volume in patients with resistant hypertension and hyperaldosteronism. A prospective clinical study, Hypertension, 55, 1137, 10.1161/HYPERTENSIONAHA.109.141531 Schmieder, 2005, The role on non-haemodynamic factors in the genesis of LVH, Nephron Dial Transplant, 20, 2610, 10.1093/ndt/gfi190 Sarafidis, 2008, Resistant hypertension: an overview of evaluation and treatment, J Am Coll Cardiol, 52, 1749, 10.1016/j.jacc.2008.08.036 Salles, 2008, Prognostic influence of office and ambulatory blood pressure in resistant hypertension, Arch Intern Med, 168, 2340, 10.1001/archinte.168.21.2340